Wound Fluid Induces Cancer Cell Growth: A Mechanism for Recurrence?

Background: The process of wound healing after surgical resection of breast cancer may contribute to the development of local recurrence and possibly even metastases. Local recurrence after lumpectomy or mastectomy occurs most frequently near the surgical scar, leading to the hypothesis that the wound itself may promote the growth of residual disease. Some studies even suggest that removal of the primary tumor can accelerate progression of occult metastases. Two studies have shown that wound fluid can stimulate the growth of cancer cells and that differing cancer cell lines may be stimulated by differing wound fluid. A major criticism of these studies is that the activity of the wound fluid was compared to either the patient serum, which is likely less inflammatory than the wound fluid, or to serum free media. Thus, these studies did not define whether the inflammatory component of wound fluid alone is sufficient to stimulate cancer cell growth or whether the ability was specific to breast derived wound fluid. In this pilot study wound fluid was collected from 10 patients who had undergone unilateral mastectomy with abdominal flap reconstruction or bilateral mastectomy where one breast had known cancer and the contralateral did not. In the unilateral mastectomy patients, the fluid from the involved breast was compared to the fluid from the abdominal drain. In the bilateral mastectomy patients the fluid from the breast with cancer was compared with the fluid from the prophylactically removed breast. The effect of wound fluid on the growth of breast cancer cells was analyzed for each patient.Methods: Fluid from each breast and abdominal drain were collected 24 and 48 hours after surgery and their ability to promote growth of 6 different breast cancer cell lines was tested. In addition, the ability of the 48 hour wound fluid to stimulate colony formation of HBL-100 cells (ER-) on matrigel was established. The cytokine profile of the different wound fluid was also analyzed.Results: We found that when the ER – cells were cultured on matrigel, the breast derived fluid led to growth of invasive, branching colonies, while abdominal fluid from the same patient led to small round colonies. Further, we found that wound fluid derived from the breast where a tumor was present led to the formation of more invasive colonies than the wound fluid derived from the normal breast. Thus, we speculate that in addition to the normal cytokines and matrix metalloproteases associated with inflammation, breast wound fluid may contain additional proteins from the tumor bed microenvironment. In support of this model, we found that the protein composition of wound fluid varies from one site to another in the same patient.Conclusion: The biological activity and protein composition of wound fluid from the breast and abdomen is drastically different—such that breast wound fluid promotes growth and invasion of breast cancer cells. Thus, we hypothesize that residual disease may be stimulated to grow during the window of time after surgery when the wound fluid is produced. This transient stimulation may result in local recurrence if the nature of the residual disease is a foci cancer or acceleration of metastasis if the residual disease is disseminated into the surrounding lymph nodes or blood vessels.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3146.

Disrupted sleep the night before breast cancer surgery is associated with increased post-surgical pain

9078

Background: Despite the best clinical care, pain following breast cancer surgery is a virtually universal patient experience that can have pervasive negative consequences. Given the sometimes prolonged impact of such pain, and the large variability across patients, additional research on modifiable presurgery risk factors is needed. Recent experimental studies have found that disruption of even a single night's sleep is sufficient to increase pain sensitivity the next day in healthy volunteers. The possible negative effects of poor sleep prior to cancer surgery have not been investigated despite the likelihood that sleep may be particularly disrupted at that time. We hypothesized that sleep disruption the night before outpatient breast cancer surgery would predict increased postsurgery pain. Methods: Pain was measured in 24 female lumpectomy patients using the Brief Pain Inventory 7 days postsurgery. Sleep disruption (% of time awake in the sleep period) was measured using an actigraph device for 10 nights, commencing 3 days before surgery. Statistical analyses included correlation and multiple regression. Results: Sleep disruption was significantly greater the night before surgery than 3 nights before surgery (p=.047). Heightened sleep disruption the night before surgery predicted increased pain intensity and pain interference with daily life (r=-.44, p=.034; r=-.49, p=.015), This relationship remained significant for pain interference even after controlling for age, race, surgery duration, presurgery mood, postoperative sleep disturbance and pain medication (B=-.12, C.I. -.23 to -.02, p=.027). Conclusions: This study is the first to document adverse effects of prior sleep disruption on pain sensitivity in a clinical oncology context. Future research should explore mechanisms responsible for these effects and examine the impact of interventions to improve sleep prior to surgery.

No significant financial relationships to disclose.

Paravertebral somatic nerve block for outpatient inguinal herniorrhaphy: an expanded case report of 22 patients

BACKGROUND AND OBJECTIVES

Inguinal herniorrhaphy is a common outpatient surgical procedure. However, anesthetic techniques for inguinal herniorrhaphy are still associated with numerous side effects. Paravertebral somatic nerve block (PSNB) has the potential advantage to offer unilateral abdominal wall anesthesia and long-lasting pain relief with minimal side effects. We report our initial trial of PSNB for outpatient inguinal herniorrhaphy.

METHODS

Twenty-two patients received a PSNB at T10 to L2 using 5 mL of 0.5% bupivacaine with epinephrine 1:400,000 at each of the five levels. The onset of surgical anesthesia, duration of analgesia, side effects, and patient satisfaction with the technique were documented.

RESULTS

Surgical anesthesia occurred 15-30 minutes after injection. Two patients had a failed block. The mean +/- SD time to onset of discomfort was 14 +/- 11 hours. Time until first narcotic requirement was 22 +/- 18 hours. Thirteen patients (n = 20) had no incisional discomfort 10 hours or longer after their blocks. Three patients had epidural spread. Most patients were very satisfied with their anesthetic technique.

CONCLUSIONS

The results of our initial experience suggest that PSNB is a potentially safe and effective technique. In general, the block provided long-lasting pain relief in most patients with few side effects. A randomized study comparing paravertebral blocks with conventional anesthesia choices is suggested given the findings in this initial series of patients.

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response

BACKGROUND

Tumor cells transduced with cytokine genes provide immunogenic vaccines for cancer immunotherapy.

METHODS

A Phase I clinical trial was conducted for the specific active immunization of melanoma patients with interferon-gamma (IFN-gamma) gene-modified autologous melanoma tumor cells. Short term melanoma cultures were transduced retrovirally with the gene for human IFN-gamma. The genetically modified melanoma cells secreted biologically active IFN-gamma and showed enhanced expression of major histocompatibility complex class I and class II surface antigens. These cells were inactivated by irradiation (50 gray) and were cryopreserved for the vaccine. Twenty melanoma patients were enrolled in this clinical trial. The immunizations were administered in escalating doses once every 2 weeks for 3 months. The first and second injections consisted of 2 million cells, followed by 6 million for the third and fourth injections, and then 18 million for the fifth and sixth injections. The humoral immune responses of the patients were assessed by enzyme-linked immunoadsorbent assay, radioimmunoassay, and radioimmunoprecipitation.

RESULTS

Thirteen of the 20 patients completed the immunization protocol. Eight of these 13 patients showed a humoral immunoglobulin (Ig)G response against autologous and allogeneic melanoma cells. The other five patients either had no detectable antimelanoma antibodies or showed a weak IgG response that did not rise significantly above the preimmune level. All the sera contained low or undetectable levels of antimelanoma IgM antibodies. The IgG response increased progressively in titer during the course of immunization. The positive sera showed preferentially strong binding to melanoma cell lines and some cross-reactivity to nonmelanoma tumors. A 75-80 kD antigen on melanoma cells was immunoprecipitated by postimmune sera of 3 of the responding patients. Preimmune sera from these three patients and sera from other patients immunized with a standard nontransduced melanoma cell vaccine failed to precipitate this antigen. Two patients with significant increases in serum IgG had clinical tumor regression, and two additional patients with low serum IgG response had transient shrinkage of nodular disease during therapy.

CONCLUSIONS

These data suggest that gene therapy with IFN-gamma-transduced melanoma cells is safe and worthy of further investigation in patients with less advanced stage malignant melanoma. The ability to monitor changes in the humoral responses of the immunized patients has been demonstrated.

Pancreatography and the surgical management of pseudocysts

Endoscopic pancreatography has played a dominant role in the evolution of surgical treatment of pancreatic pseudocysts. This article presents an algorithm for the management of pseudocyst disease, focusing on pancreatography and elective treatment. Pancreatography's roles in refining operative strategies, identifying associated pancreatic and biliary disease, and predicting outcome of nonoperative treatment are reviewed.